Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Mesothelioma
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
Related Questions
In light of recent retrospective data from France on EGFR TKIs use with PPIs showing negative outcomes in NSCLC patients would you consider discontinuing PPIs or changing PPIs to H2 inhibitors?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
How do you treat Stage IIIC T4N3 NSCLC?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240mg versus 960mg dose of sotorasib?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
